Monod Bio

We are excited to announce a $750,000 grant from Grand Challenges, an initiative of the Gates Foundation, to develop a next-generation diagnostic test for preeclampsia. The new diagnostic will be built on Monod Bio’s proprietary NovoLISA™ platform, which combines two cutting-edge technologies: NovoBody™ binders and LuxSit™. “Monod Bio’s NovoBody™ Binders represent a new class of computationally designed proteins that function as next-generation antibody replacements, while LuxSit™ is a de novo luciferase reporter system,” noted Alfredo Quijano Rubio Chief Scientific Officer of Mondo Bio. “Together, these technologies create a rapid, one-step, ‘mix-and-read’ format that delivers results in under 15 minutes without the need for complex wash steps.” Designed for use at the point-of-care, the diagnostic test will run on a simple, one-step system that brings fast, affordable testing to low-resource settings. Read the full press release here: https://lnkd.in/gGstuGSV #Biotechnology #ProteinDesign #GlobalHealth #Diagnostics #Preeclampsia

We are pleased to announce the appointment of Timothy I. Still as our Executive Chairman. Tim brings more than 35 years industry experience in medical diagnostics and life science tools with a career spanning numerous CEO and Board appointments. "We are confident that Tim's deep expertise in executing highly focused commercial strategies will be invaluable as we enter an aggressive growth phase and cement our position at the forefront of AI-powered protein design in diagnostics and life science tools," said Daniel-Adriano S., CEO and Founder of Monod Bio. Read the full press release here: https://lnkd.in/gxUemw4g #monodbio #proteindesign #biotechnology #appointments

We are pleased to announce the appointment of Timothy I. Still as our Executive Chairman. Tim brings more than 35 years industry experience in medical diagnostics and life science tools with a career spanning numerous CEO and Board appointments. "We are confident that Tim's deep expertise in executing highly focused commercial strategies will be invaluable as we enter an aggressive growth phase and cement our position at the forefront of AI-powered protein design in diagnostics and life science tools," said Daniel-Adriano S., CEO and Founder of Monod Bio. Read the full press release here: https://lnkd.in/gxUemw4g #monodbio #proteindesign #biotechnology #appointments

We are excited to announce a $1.5M grant from the Gates Foundation to develop a rapid diagnostic for tuberculosis. The new test will be created using Monod Bio’s proprietary AI-based protein design platform, which allows for the creation of NovoBodies™, a new class of computationally designed proteins that act as next-generation antibody replacements. "With this grant from the Gates Foundation, we are pioneering a new era of diagnostics by building proteins from the ground up, with precise control over their function,” said Daniel-Adriano S. Read the full press release here: https://lnkd.in/gsEyXAiH #Biotechnology #ProteinDesign #GlobalHealth #Diagnostics #Tuberculosis

Our Senior Director of Business Development, Carl Walkey, PhD, recently spoke at Life Science Washington’s annual Life Science Innovation Northwest conference. He introduced Monod Bio’s suite of platform technologies—LuxSit™ Pro, NovoBody™, NovoLISA, and Protein Mimetics—all of which are available for partnering opportunities. As a spin-out from David Baker’s lab at the Institute for Protein Design, University of Washington, we were honored to present alongside four other Baker lab spin-outs in the Computational Protein Design session. It was inspiring to see the wide range of applications that computational protein design is enabling—from food and materials to diagnostics and therapeutics. We’re proud to be part of this transformational movement. Check out the photo below of Carl presenting our NovoBody™ Duo technology in action! #proteinDesign #DavidBaker #ComputationalProteinDesign #UW #LSINW #NovoBody #MonodBio

Our Chief Scientific Officer & Co-Founder, Alfredo Quijano Rubio, PhD, will be presenting at the Cytokine-Based Drug Development Summit May 15-16. Join him and other expert speakers in Boston for cutting-edge insights into cytokine-based drug development. We hope to see you there! #MonodBio #Cytokine #DrugDevelopment #Boston Full session details in the comments!

Our Chief Scientific Officer & Co-Founder, Alfredo Quijano Rubio, PhD, along with Indrani Chakraborty, will be presenting on our groundbreaking NovoBody Platform on March 19th. Don’t miss this opportunity to learn more! Register here: https://lnkd.in/gDNNiiDu

Antibodies revolutionized molecular binding, but innovation doesn't stand still. Monod Bio's NovoBody™ Binder platform represents a revolutionary leap forward, surpassing traditional barriers to unlock the full potential of your assays. #AssayDevelopment #MolecularBinding #Innovation #NovoBody Check out more info here: https://lnkd.in/g5UpukUH